Abstract |
A single intrathecal dose of adenosine 2A receptor (A2AR) agonist was previously reported to produce a multi-week reversal of allodynia in two different models of neuropathic pain in addition to downregulating glial activation markers in the spinal cord. We aimed to determine whether a single intrathecal administration of an A2AR agonist was able to attenuate motor symptoms induced by experimental autoimmune encephalopathy. Two A2AR agonists ( CGS21680 and ATL313) significantly attenuated progression of motor symptoms following a single intrathecal administration at the onset of motor symptoms. OX-42, a marker of microglial activation, was significantly attenuated in the lumbar spinal cord following A2AR administration compared to vehicle. Therefore, A2AR agonists attenuate motor symptoms of EAE by acting on A2AR in the spinal cord.
|
Authors | Lisa C Loram, Keith A Strand, Frederick R Taylor, Evan Sloane, Anne-Marie Van Dam, Jayson Rieger, Steven F Maier, Linda R Watkins |
Journal | Brain, behavior, and immunity
(Brain Behav Immun)
Vol. 46
Pg. 50-4
(May 2015)
ISSN: 1090-2139 [Electronic] Netherlands |
PMID | 25653191
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- ATL 313
- Adenosine A2 Receptor Agonists
- Phenethylamines
- Piperidines
- 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
- Adenosine
|
Topics |
- Adenosine
(analogs & derivatives, pharmacology, therapeutic use)
- Adenosine A2 Receptor Agonists
(pharmacology, therapeutic use)
- Animals
- Encephalomyelitis, Autoimmune, Experimental
(drug therapy)
- Male
- Microglia
(drug effects)
- Paralysis
(drug therapy)
- Phenethylamines
(pharmacology, therapeutic use)
- Piperidines
(pharmacology, therapeutic use)
- Rats
- Spinal Cord
(drug effects)
|